All News

Three little words that are no less terrifying the second time around.

Treatment with the experimental agent elotuzumab in combination with Revlimid and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma in a phase 1b/2 study.

Tasigna in combination with chemotherapy elicited a complete hematological remissions (CHR) in 87 percent of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph-positive ALL).

In a first-in-human study, the drug AG-221 generated long-lasting remissions in patients with acute myeloid leukemia (AML).

Zydelig was approved for several recurrent B-cell cancers, and now new data shows the drug also creates a response in older patients newly diagnosed with CLL or SLL.

Following treatment with high-dose chemotherapy and stem cell transplant, patients with relapsed and difficult-to-treat Hodgkin lymphoma who received Adcetris had a higher likelihood of progression-free survival at two years.

Anti-CD38 monoclonal antibodies continue to demonstrate promise across a variety of settings, generating excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.

Adding the proteasome inhibitor Kyprolis (carfilzomib) after Revlimid (lenalidomide) in patients with relapsed multiple myeloma showed significant delay of disease progression.

An early study in patients with Hodgkin lymphoma that had progressed on several lines of treatment found that the immunotherapy Keytruda (pembrolizumab) elicited a remarkable response.

Kathleen Vogt is a dynamo when it comes to advocating for her husband Gary, who was diagnosed with a myeloprolifertive neoplasm (MPN) a number of years ago.

The CAR T-cell therapy CTL019 demonstrated an impressive complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

A small phase 1 trial found that certain patients with classical Hodgkin lymphoma (cHL), who had previously failed three or more therapies, responded to the immunotherapy nivolumab.

Caregivers, patient advocates and a clinical researcher were honored at CURE's MPN Heroes event held on Dec. 5 in San Francisco.

The FDA has approved Jakafi (ruxolitinib) as a treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea, based on findings from the phase 3 RESPONSE trial.

The FDA approved the anti-CD19 immunotherapy Blincyto (blinatumomab) as a treatment for Philadelphia chromosome-negative acute lymphoblastic leukemia.

This Thanksgiving, I wish you all moments filled wth friendship, togetherness, peace and HOPE and the gift of many blessings, great and small.

TheAnswerToCancer.org website offers information to patients solely about cancer immunotherapy.

A clinical trial, a targeted mutation and a little hope

The first few weeks following a cancer diagnosis can be the most challenging.

Consistency, truthfulness and age-appropriate conversations are vital for children in adjusting to a parent's cancer survivorship.

To promote physical, emotional and spiritual health while moving into survivorship, a number of caregiver support organizations offer recommendations.

Despite the lack of data to justify them, periodic surveillance PET scans during remission are performed frequently.

For caregivers, the challenges of caring for patients become more complicated when the cancer returns and the patient approaches the end of life.

Physical activity may be as powerful as anything that comes from a bottle, but how much and how often is as individual as every pill in your medicine cabinet.

The CAR T-cell therapy JCAR015 received breakthrough therapy designation as a treatment for patients with relapsed or refractory B-cell ALL.

When caring for someone who has undergone brain surgery, practice patience and ask for support.

Experts offer suggestions on post-surgery care after brain cancer.

Gaining access to that top-notch doctor or medical center can present a larger hurdle for someone with an uncommon malignancy, but it is possible with a few tips.